140 related articles for article (PubMed ID: 35965581)
1. Case report: ISL2 is involved in malignant transformation in a patient with multiple relapsed oligodendroglioma.
Chen SN; Wang Z; Zhou DS; Liu XQ; Mai TY; Dong ZX; Li M; Zhang XD; Qi L
Front Oncol; 2022; 12():969191. PubMed ID: 35965581
[TBL] [Abstract][Full Text] [Related]
2. ISL2 modulates angiogenesis through transcriptional regulation of ANGPT2 to promote cell proliferation and malignant transformation in oligodendroglioma.
Qi L; Wang ZY; Shao XR; Li M; Chen SN; Liu XQ; Yan S; Zhang B; Zhang XD; Li X; Zhao W; Pan JA; Zhao B; Zhang XD
Oncogene; 2020 Sep; 39(37):5964-5978. PubMed ID: 32753650
[TBL] [Abstract][Full Text] [Related]
3. The U2AF2 /circRNA ARF1/miR-342-3p/ISL2 feedback loop regulates angiogenesis in glioma stem cells.
Jiang Y; Zhou J; Zhao J; Zhang H; Li L; Li H; Chen L; Hu J; Zheng W; Jing Z
J Exp Clin Cancer Res; 2020 Sep; 39(1):182. PubMed ID: 32894165
[TBL] [Abstract][Full Text] [Related]
4. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
Capper D; Reuss D; Schittenhelm J; Hartmann C; Bremer J; Sahm F; Harter PN; Jeibmann A; von Deimling A
Acta Neuropathol; 2011 Feb; 121(2):241-52. PubMed ID: 21069360
[TBL] [Abstract][Full Text] [Related]
5. Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status.
Ohno M; Narita Y; Miyakita Y; Okita Y; Matsushita Y; Yoshida A; Fukushima S; Ichimura K; Kayama T; Shibui S
Brain Tumor Pathol; 2012 Oct; 29(4):183-91. PubMed ID: 22790483
[TBL] [Abstract][Full Text] [Related]
6. Molecular profile of tumors with oligodendroglial morphology: Clinical relevance.
Geevar T; Pai R; Chacko G; Malepathi K; Patel B; John J; Chacko AG; Balakrishnan R; John S
Neurol India; 2018; 66(6):1726-1731. PubMed ID: 30504574
[TBL] [Abstract][Full Text] [Related]
7. High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q Co-Deletion and Favorable Prognosis in Oligodendroglioma.
Sathornsumetee S; Cheunsuchon P; Sangruchi T
World Neurosurg; 2016 Jul; 91():518-523.e1. PubMed ID: 26960282
[TBL] [Abstract][Full Text] [Related]
8. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-inducible factor-1-regulated protein expression and oligodendroglioma patient outcome: comparison with established biomarkers and preoperative UCSF low-grade scoring system.
Abraham S; Hu N; Jensen R
J Neurooncol; 2012 Jul; 108(3):459-68. PubMed ID: 22396073
[TBL] [Abstract][Full Text] [Related]
10. Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma.
Çelik S; Öven BB; Demir MK; Yılmaz EÇ; Kanan D; Özdamarlar U; Emirzeoglu L; Yapıcıer Ö; Kılıç T
Clin Neurol Neurosurg; 2021 Aug; 207():106745. PubMed ID: 34146841
[TBL] [Abstract][Full Text] [Related]
11. Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.
Habiba U; Sugino H; Yordanova R; Ise K; Tanei ZI; Ishida Y; Tanikawa S; Terasaka S; Sato KI; Kamoshima Y; Katoh M; Nagane M; Shibahara J; Tsuda M; Tanaka S
Acta Neuropathol Commun; 2021 May; 9(1):95. PubMed ID: 34020723
[TBL] [Abstract][Full Text] [Related]
12. The Applicability of Haarlem Integrated Diagnostic System in Diffuse Glial Tumors and Molecular Methods Affecting Prognosis.
Kaya Terzi N; Yılmaz İ; Öz AB
Balkan Med J; 2019 Jul; 36(4):222-228. PubMed ID: 30592195
[TBL] [Abstract][Full Text] [Related]
13. The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients.
Hacisalihoglu P; Kucukodaci Z; Gundogdu G; Bilgic B
Turk Neurosurg; 2017; 27(5):682-689. PubMed ID: 27651340
[TBL] [Abstract][Full Text] [Related]
14. Proteomic analysis of oligodendrogliomas expressing a mutant isocitrate dehydrogenase-1.
Thirant C; Varlet P; Lipecka J; Le Gall M; Broussard C; Chafey P; Studler JM; Lacombe J; Lions S; Guillaudeau A; Camoin L; Daumas-Duport C; Junier MP; Chneiweiss H
Proteomics; 2011 Nov; 11(21):4139-54. PubMed ID: 21898821
[TBL] [Abstract][Full Text] [Related]
15. Integrated proteomic analysis of low-grade gliomas reveals contributions of 1p-19q co-deletion to oligodendroglioma.
Wong D; Lee TH; Lum A; Tao VL; Yip S
Acta Neuropathol Commun; 2022 May; 10(1):70. PubMed ID: 35526077
[TBL] [Abstract][Full Text] [Related]
16. Imaging growth as a predictor of grade of malignancy and aggressiveness of IDH-mutant and 1p/19q-codeleted oligodendrogliomas in adults.
Roux A; Tauziede-Espariat A; Zanello M; Peeters S; Zah-Bi G; Parraga E; Edjlali M; Lechapt E; Shor N; Bellu L; Berzero G; Dormont D; Dezamis E; Chretien F; Oppenheim C; Sanson M; Varlet P; Capelle L; Dhermain F; Pallud J
Neuro Oncol; 2020 Jul; 22(7):993-1005. PubMed ID: 32025725
[TBL] [Abstract][Full Text] [Related]
17. IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy.
Iwadate Y; Matsutani T; Hirono S; Ikegami S; Shinozaki N; Saeki N
J Neurooncol; 2015 Sep; 124(3):493-500. PubMed ID: 26243269
[TBL] [Abstract][Full Text] [Related]
18. The impact of extent of resection on malignant transformation of pure oligodendrogliomas.
Snyder LA; Wolf AB; Oppenlander ME; Bina R; Wilson JR; Ashby L; Brachman D; Coons SW; Spetzler RF; Sanai N
J Neurosurg; 2014 Feb; 120(2):309-14. PubMed ID: 24313617
[TBL] [Abstract][Full Text] [Related]
19. A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.
Steidl E; Filipski K; Zeiner PS; Wagner M; Fokas E; Forster MT; Ronellenfitsch MW; Divé I; Steinbach JP; Harter PN; Bähr O
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2373-2383. PubMed ID: 33538917
[TBL] [Abstract][Full Text] [Related]
20. Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas.
Yi L; Fan X; Li J; Yuan F; Zhao J; Nistér M; Yang X
Aging (Albany NY); 2021 Jan; 13(3):3645-3660. PubMed ID: 33493139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
